Cas number: 330784-47-9 Molecular Formula： C23H26ClN7O3
Cas number: 330784-47-9 Molecular Formula： C23H26ClN7O3
Looking for a reliable factory to buy high-quality product cas number: 330784-47-9? Look no further! Our factory offers C23H26ClN7O3 with competitive prices.
is a highly selective PDE5 inhibitor with IC50 of 1 nM.(Zepeed) was approved by the Korean Health Ministry for the treatment of erectile dysfunction (ED) in August 2011.is a highly selective type 5 phosphodiesterase (PDE5) inhibitor. is reported to be the most selective PDE5 inhibitor on the market. The onset of Tmax and half-life also varies among the marketed PDE5 inhibitors. Sildenafil has a Tmax at 1 h and a half-life of 3–5 h. Vardenafil is somewhat similar with a Tmax of 0.6 h and a half-life of 4–6 h. Tadalafil has the longest half-life among the marketed drugs with a half-life of 17 h. has a fast onset of action reaching Tmax in 0.6 h with a half-life of 1.2 h. A synthesis of (TA-1790) is described in the patent literature. The main elimination route of is through the bile and feces. was also found to be reabsorbed through enterohepatic recirculation.
Melting Point
150-152°C
Density
1.372
storage temp
Sealed in dry,Store in freezer, under -20°C
solubility
DMSO (Slightly), Methanol (Slightly, Heated)
optical activity
N/A
Appearance
White to Off-White
Purity
≥98%
A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.
(Zepeed) was approved by the Korean Health Ministry for the treatment of erectile dysfunction (ED) in August 2011.is a highly selective type 5 phosphodiesterase (PDE5) inhibitor. is reported to be the most selective PDE5 inhibitor on the market. The onset of Tmax and half-life also varies among the marketed PDE5 inhibitors. Sildenafil has a Tmax at 1 h and a half-life of 3–5 h. Vardenafil is somewhat similar with a Tmax of 0.6 h and a half-life of 4–6 h. Tadalafil has the longest half-life among the marketed drugs with a half-life of 17 h. has a fast onset of action reaching Tmax in 0.6 h with a half-life of 1.2 h. A synthesis of (TA-1790) is described in the patent literature. The main elimination route of is through the bile and feces. was also found to be reabsorbed through enterohepatic recirculation.
